Sanofi and CytoReason target IBD in expanded collaboration

Sanofi expanded its collaboration with Israeli molecular data expert CytoReason Monday, entering into a multimillion-dollar deal to license the latter’s inflammatory bowel disease (IBD) model.

The deal builds on a 2021 agreement that focused on understanding the heterogeneity of asthma patients to identify asthma endotypes. Financial details of both agreements remain undisclosed.